Compare NXPL & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NXPL | COCH |
|---|---|---|
| Founded | 1997 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Blank Checks |
| Sector | Telecommunications | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.8M | 51.3M |
| IPO Year | 2011 | 2021 |
| Metric | NXPL | COCH |
|---|---|---|
| Price | $7.20 | $6.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $19.67 |
| AVG Volume (30 Days) | 19.7K | ★ 31.8K |
| Earning Date | 11-12-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 35.29 | 17.45 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,869,558.00 | $241,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $46.77 | $15.33 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 2.50 | ★ 7.11 |
| 52 Week Low | $0.34 | $4.72 |
| 52 Week High | $9.94 | $47.70 |
| Indicator | NXPL | COCH |
|---|---|---|
| Relative Strength Index (RSI) | 37.29 | 18.42 |
| Support Level | $5.54 | $4.72 |
| Resistance Level | $7.24 | $7.46 |
| Average True Range (ATR) | 0.83 | 0.46 |
| MACD | -0.12 | 1.03 |
| Stochastic Oscillator | 38.88 | 43.44 |
NextPlat Corp is an e-commerce and healthcare company. The company operates in two segments: e-Commerce Operations involves acquiring and leasing an e-commerce platform; and Healthcare Operations provides TPA, data management, COVID-19 related diagnostics and vaccinations, prescription pharmaceuticals, and Others.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.